2096 Stock Overview
Engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2096 from our risk checks.
Simcere Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$6.78 |
| 52 Week High | HK$7.63 |
| 52 Week Low | HK$4.94 |
| Beta | 0.44 |
| 11 Month Change | -0.29% |
| 3 Month Change | 28.41% |
| 1 Year Change | -10.55% |
| 33 Year Change | -26.22% |
| 5 Year Change | n/a |
| Change since IPO | -38.25% |
Recent News & Updates
Recent updates
Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing
Jul 29
Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems
May 01Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market
Dec 29Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates
Aug 28Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%?
Jun 03Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically
Apr 06Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096)
Jan 10With EPS Growth And More, Simcere Pharmaceutical Group (HKG:2096) Makes An Interesting Case
Aug 16Simcere Pharmaceutical Group (HKG:2096) Has Announced A Dividend Of HK$0.18
Jun 27Shareholder Returns
| 2096 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -4.8% | 0.8% | 0.4% |
| 1Y | -10.6% | -7.5% | 12.0% |
Return vs Industry: 2096 underperformed the Hong Kong Pharmaceuticals industry which returned -7.5% over the past year.
Return vs Market: 2096 underperformed the Hong Kong Market which returned 12% over the past year.
Price Volatility
| 2096 volatility | |
|---|---|
| 2096 Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 2096 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2096's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 6,412 | Jinsheng Ren | www.simcere.com |
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, a simnotrelvir tablets/ritonavir tablets.
Simcere Pharmaceutical Group Limited Fundamentals Summary
| 2096 fundamental statistics | |
|---|---|
| Market cap | HK$17.06b |
| Earnings (TTM) | -HK$1.18b |
| Revenue (TTM) | HK$6.81b |
2.5x
P/S Ratio-14.3x
P/E RatioIs 2096 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2096 income statement (TTM) | |
|---|---|
| Revenue | CN¥6.34b |
| Cost of Revenue | CN¥1.45b |
| Gross Profit | CN¥4.88b |
| Other Expenses | CN¥5.99b |
| Earnings | -CN¥1.10b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.44 |
| Gross Margin | 77.05% |
| Net Profit Margin | -17.39% |
| Debt/Equity Ratio | 14.5% |
How did 2096 perform over the long term?
See historical performance and comparison